Cellectar Biosciences, Inc. (CLRB) financial statements (2022 and earlier)

Company profile

Business Address 100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,70440,34546,77853,62757,16518,84222,450
Cash and cash equivalents35,70440,34546,77853,62757,16518,84222,450
Other undisclosed current assets8671,048347775774961594
Total current assets:36,57141,39347,12554,40257,94019,80323,044
Noncurrent Assets
Operating lease, right-of-use asset 225245264282300317
Property, plant and equipment344254287318356375411
Long-term investments and receivables757575757521981
Long-term investments757575757521981
Other noncurrent assets66666  
Other undisclosed noncurrent assets205      
Total noncurrent assets:630560613663720894809
TOTAL ASSETS:37,20241,95347,73855,06558,65920,69723,853
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,8553,0343,3914,8963,4433,8393,207
Accounts payable1,415   1,429  
Accrued liabilities55   377  
Employee-related liabilities504   850  
Other undisclosed accounts payable and accrued liabilities1,8813,0343,3914,8967873,8393,207
Debt      113
Other undisclosed current liabilities135131127124120116 
Total current liabilities:3,9903,1663,5185,0203,5633,9563,320
Noncurrent Liabilities
Long-term debt and lease obligation166202236269302517548
Long-term debt, excluding current maturities     184184
Operating lease, liability166202236269302333364
Other undisclosed noncurrent liabilities(166)(202)(236)(269) (333) 
Total noncurrent liabilities: 202236269302517548
Total liabilities:4,1573,3683,7555,2893,8654,4733,867
Stockholders' equity
Stockholders' equity attributable to parent, including:33,04538,58543,98349,77654,79516,22419,985
Preferred stock     1,1481,148
Common stock1111000
Additional paid in capital182,560182,182174,506171,161161,534138,236138,088
Accumulated deficit (144,980)(139,161)(133,133)(126,775)(123,160)(119,251)
Other undisclosed stockholders' equity attributable to parent(149,516)1,3828,63811,74720,036  
Total stockholders' equity:33,04538,58543,98349,77654,79516,22419,985
TOTAL LIABILITIES AND EQUITY:37,20241,95347,73855,06558,65920,69723,853

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(5,923)(5,820)(6,029)(6,360)(3,800)(3,910)(3,622)
Operating loss:(5,923)(5,820)(6,029)(6,360)(3,800)(3,910)(3,622)
Nonoperating income5112184010
Other undisclosed income from continuing operations before equity method investments, income taxes    185  
Net loss:(5,918)(5,819)(6,028)(6,357)(3,430)(3,910)(3,612)
Other undisclosed net loss attributable to parent    (185)  
Net loss available to common stockholders, diluted:(5,918)(5,819)(6,028)(6,357)(3,615)(3,910)(3,612)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(5,918)(5,819)(6,028)(6,357)(3,430)(3,910)(3,612)
Comprehensive loss, net of tax, attributable to parent:(5,918)(5,819)(6,028)(6,357)(3,430)(3,910)(3,612)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: